SK Biopharmaceuticals Co., Ltd. (KRX:326030)

SK Biopharmaceuticals Revenue

SK Biopharmaceuticals had revenue of 227.89B KRW in the quarter ending March 31, 2026, with 57.84% growth. This brings the company's revenue in the last twelve months to 790.25B, up 36.72% year-over-year. In the year 2025, SK Biopharmaceuticals had annual revenue of 706.74B with 29.06% growth.

• Revenue (ttm): 790.25B
• Revenue Growth: +36.72%
• P/S Ratio: 8.76
• Revenue / Employee: 3.21B
• Employees: 246
• Market Cap: 6.92T

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	706.74B	159.14B	29.06%
Dec 31, 2024	547.60B	192.70B	54.30%
Dec 31, 2023	354.89B	108.71B	44.16%
Dec 31, 2022	246.18B	-172.47B	-41.20%
Dec 31, 2021	418.64B	392.65B	1,510.23%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 3, 2026

Data Sources Report a data error